Metformin: New Preparations and Nonglycemic Benefits

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2017 Jan 25

PMID 28116648

Citations 37

Authors

Yoshihito Fujita

Nobuya Inagaki

Affiliations

Soon will be listed here.

Abstract

Metformin has been widely used for over 5 decades. New preparations have been developed for possible enhancement of efficiency, tolerability, and pleiotropic nonglycemic effects. Extended-release metformin has contributed to adherence and improved gastrointestinal tolerability. Delayed-release metformin acts in the lower gastrointestinal tract and exerts glucose-lowering effects at lower plasma metformin levels, which might suggest use of this biguanide in patients with chronic kidney disease. Metformin is also known to have numerous nonglycemic effects. Results of the UK Prospective Diabetes Study indicate improvements in cardiovascular outcome and reduced total mortality independent of glycemic control. Anticancer effects of metformin have been discussed and many clinical trials are on-going. Metformin is noted for its beneficial effects on lifespan extension and on disorders due to increased insulin resistance. Further investigations, including randomized control trials in nondiabetic individuals, are required to demonstrate the nonglycemic effects of metformin.

Citing Articles

Protein Tyrosine Phosphatase 1B (PTP1B): A Comprehensive Review of Its Role in Pathogenesis of Human Diseases.

Kolodziej-Sobczak D, Sobczak L, Laczkowski K Int J Mol Sci. 2024; 25(13).

PMID: 39000142 PMC: 11241624. DOI: 10.3390/ijms25137033.

Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.

Mac Curtain B, OBrien L, El Sherif O, Mc Cormack A, Carolan E, Ryan J Gastroenterol Hepatol Bed Bench. 2024; 17(1):17-27.

PMID: 38737926 PMC: 11080689. DOI: 10.22037/ghfbb.v17i1.2899.

Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program.

Molteni L, Marelli G, Castagna G, Brambilla L, Acerbis M, Alberghina F Endocr Metab Immune Disord Drug Targets. 2024; 24(12):1422-1430.

PMID: 38425116 PMC: 11348454. DOI: 10.2174/0118715303294909240221102552.

Aerobic exercise and metformin on intermuscular adipose tissue (IMAT): insights from multimodal MRI and histological changes in prediabetic rats.

Yu F, Xing C, Fan Y, Liu Y, Su P, Yang Q Diabetol Metab Syndr. 2023; 15(1):221.

PMID: 37899436 PMC: 10614363. DOI: 10.1186/s13098-023-01183-x.

Insights Into Metformin XR Pharmacotherapy Knowledge Among Community Pharmacists: A Cross-Sectional Study.

Jairoun A, Al-Hemyari S, Shahwan M, Hassan N, Zyoud S, Jaber A Clin Med Insights Endocrinol Diabetes. 2023; 16:11795514231203913.

PMID: 37846366 PMC: 10576939. DOI: 10.1177/11795514231203913.

References

Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269-73. DOI: 10.1158/0008-5472.CAN-06-1500. View

Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M . DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. Biochem Biophys Res Commun. 2015; 460(4):1047-52. DOI: 10.1016/j.bbrc.2015.03.148. View

Anabtawi A, Miles J . METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS. Endocr Pract. 2016; 22(8):999-1007. DOI: 10.4158/EP151145.RA. View

Fujioka K, Brazg R, Raz I, Bruce S, Joyal S, Swanink R . Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind,.... Diabetes Obes Metab. 2005; 7(1):28-39. DOI: 10.1111/j.1463-1326.2004.00369.x. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

Donnelly L, Morris A, Pearson E . Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009; 11(4):338-42. DOI: 10.1111/j.1463-1326.2008.00973.x. View

Misbin R, Green L, Stadel B, Gueriguian J, Gubbi A, Fleming G . Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998; 338(4):265-6. DOI: 10.1056/NEJM199801223380415. View

Fujioka K, Pans M, Joyal S . Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003; 25(2):515-29. DOI: 10.1016/s0149-2918(03)80093-0. View

. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003; 26(4):977-80. PMC: 1360737. DOI: 10.2337/diacare.26.4.977. View

10.

Owen M, Doran E, Halestrap A . Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000; 348 Pt 3:607-14. PMC: 1221104. View

11.

Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P . Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011; 71(13):4366-72. DOI: 10.1158/0008-5472.CAN-10-1769. View

12.

. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008; 23(3):462-77. DOI: 10.1093/humrep/dem426. View

13.

Blonde L, Dailey G, Jabbour S, Reasner C, Mills D . Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004; 20(4):565-72. DOI: 10.1185/030079904125003278. View

14.

Boulton D, Smith C, Li L, Huang J, Tang A, LaCreta F . Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig. 2011; 31(9):619-30. DOI: 10.2165/11590290-000000000-00000. View

15.

Guo L, Guo X, Li Y, Hong X, Jiang X, Su Q . Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients. Diabetes Metab Syndr. 2016; 10(3):137-42. DOI: 10.1016/j.dsx.2016.01.004. View

16.

Misso M, Teede H . Metformin in women with PCOS, cons. Endocrine. 2014; 48(2):428-33. DOI: 10.1007/s12020-014-0394-8. View

17.

McCreight L, Bailey C, Pearson E . Metformin and the gastrointestinal tract. Diabetologia. 2016; 59(3):426-35. PMC: 4742508. DOI: 10.1007/s00125-015-3844-9. View

18.

Bonora E, Cigolini M, Bosello O, Zancanaro C, Capretti L, Zavaroni I . Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin. 1984; 9(1):47-51. DOI: 10.1185/03007998409109558. View

19.

Mair W, Dillin A . Aging and survival: the genetics of life span extension by dietary restriction. Annu Rev Biochem. 2008; 77:727-54. DOI: 10.1146/annurev.biochem.77.061206.171059. View

20.

Yoon K, Lee J, Kim J, Cho J, Choi Y, Ko S . Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368(9548):1681-8. DOI: 10.1016/S0140-6736(06)69703-1. View